呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

Cell Res：瑞德西韦和磷酸氯喹能在体外有效抑制新型冠状病毒（2019-nCoV））

2020-02-04 MedSci MedSci

瑞德西韦氯喹
关注

2020年2月4日，中国科学院武汉病毒研究所/生物安全大科学研究中心与军事科学院军事医学研究院国家应急防控药物工程技术研究中心开展联合研究，在抑制2019新型冠状病毒（2019-nCoV）药物筛选方面取得重要进展。发现瑞德西韦和磷酸氯喹能在体外有效抑制新型冠状病毒（2019-nCoV），发表在Cell Research上。在Vero E6细胞上，瑞德西韦（Remdesivir, GS-5734）对

2020年2月4日，中国科学院武汉病毒研究所/生物安全大科学研究中心与军事科学院军事医学研究院国家应急防控药物工程技术研究中心开展联合研究，在抑制2019新型冠状病毒（2019-nCoV）药物筛选方面取得重要进展。发现瑞德西韦和磷酸氯喹能在体外有效抑制新型冠状病毒（2019-nCoV），发表在Cell Research上。

研究共测试了7种常见的抗病毒相关药物。在Vero E6细胞上，瑞德西韦（Remdesivir, GS-5734）对2019-nCoV的半数有效浓度EC50=0.77μM，选择指数SI大于129（EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87）；磷酸氯喹（Chloroquine）的EC50=1.13μM，SI大于88 (EC50 = 1.13 μM; CC50 > 100 μM, SI > 88.50) ，说明上述两种药物在细胞水平上能有效抑制2019-nCoV的感染，其在人体上的作用还有待临床验证。其它药物抗2019-nCoV的感染不太理想，包括利巴韦林,法维拉韦,喷昔洛韦

Fig. 1


瑞德西韦（Remdesivir）是核苷类似物，起初是吉利德公司开发用于埃博拉病毒的治疗，显示出一定的效果，但是总体疗效不如相关单克隆抗体，但安全性良好。在美国的个案报道中发现对新型冠状病毒有很好的作用，目前正在国内开展临床试验。

磷酸氯喹（Chloroquine）于上个世纪40年代起用于治疗疟疾，后用于治疗类风湿性关节炎等。
目前除了瑞德西韦，还发现了磷酸氯喹、法匹拉韦，以及中成药中一批具有抗病毒活性的上市药物，比如已经上市的抗疟药磷酸氯喹，在体外研究中已经展示出了非常好的抗新型冠状病毒活性。事实上，早些年一些研究表明，氯喹具有直接的抗病毒作用，抑制了包括黄病毒，逆转录病毒（如HIV），多种冠状病毒。在SARS流行时，不少研究发现氯喹具有潜在抑制SARS病毒作用。磷酸氯喹在国内很多企业都已停厂，目前为了对抗新冠病毒，很多企业紧急复工，开始生产磷酸氯喹。

同时，李兰娟院士研究也发现阿比朵尔（阿比多尔）在10～30微摩尔浓度下，与药物未处理的对照组比较，能有效抑制冠状病毒达到60倍，并且显著抑制病毒对细胞的病变效应。达芦那韦在300微摩尔浓度下，能显著抑制病毒复制，与未用药物处理组比较，抑制效率达280倍。这两种药物的抑制病毒有效浓度均比瑞德西韦和磷酸氯喹要高。

这些药物集中发现，有助于新冠病毒的治疗！

原始出处：

Wang, M., Cao, R., Zhang, L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res (2020).   http://sci-hub.tw/10.1038/s41422-020-0282-0

De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006 Apr;4(2):291-302


Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J . 2005 Aug 22;2:69.


Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21


相关报道：

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061167, encodeId=75db206116e9e, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Jun 01 19:20:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647442, encodeId=27be164e4423e, content=<a href='/topic/show?id=ff82e385875' target=_blank style='color:#2F92EE;'>#磷酸氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73858, encryptionId=ff82e385875, topicName=磷酸氯喹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9d23409893, createdName=qidongfanjian, createdTime=Sat Feb 29 17:20:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961848, encodeId=3e4c1961848d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 12:20:00 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871557, encodeId=9ae318e155722, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 05 00:20:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
    2020-06-01 chengjn

    #有效抑制#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2061167, encodeId=75db206116e9e, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Jun 01 19:20:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647442, encodeId=27be164e4423e, content=<a href='/topic/show?id=ff82e385875' target=_blank style='color:#2F92EE;'>#磷酸氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73858, encryptionId=ff82e385875, topicName=磷酸氯喹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9d23409893, createdName=qidongfanjian, createdTime=Sat Feb 29 17:20:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961848, encodeId=3e4c1961848d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 12:20:00 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871557, encodeId=9ae318e155722, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 05 00:20:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
    2020-02-29 qidongfanjian

    #磷酸氯喹#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2061167, encodeId=75db206116e9e, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Jun 01 19:20:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647442, encodeId=27be164e4423e, content=<a href='/topic/show?id=ff82e385875' target=_blank style='color:#2F92EE;'>#磷酸氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73858, encryptionId=ff82e385875, topicName=磷酸氯喹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9d23409893, createdName=qidongfanjian, createdTime=Sat Feb 29 17:20:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961848, encodeId=3e4c1961848d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 12:20:00 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871557, encodeId=9ae318e155722, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 05 00:20:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
    2021-01-02 维他命

    #CEL#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2061167, encodeId=75db206116e9e, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Jun 01 19:20:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647442, encodeId=27be164e4423e, content=<a href='/topic/show?id=ff82e385875' target=_blank style='color:#2F92EE;'>#磷酸氯喹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73858, encryptionId=ff82e385875, topicName=磷酸氯喹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa9d23409893, createdName=qidongfanjian, createdTime=Sat Feb 29 17:20:00 CST 2020, time=2020-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961848, encodeId=3e4c1961848d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 12:20:00 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871557, encodeId=9ae318e155722, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 05 00:20:00 CST 2020, time=2020-03-05, status=1, ipAttribution=)]
    2020-03-05 zhaozhouchifen

    #Cell#

    0

相关资讯

中日友好医院：在武汉牵头开展瑞德西韦治疗新冠病毒临床研究

关于新型冠状病毒的研究治疗有了新进展。2月2日，中日友好医院（简称“中日医院”）官网发布消息称，中日友好医院在武汉疫区牵头开展瑞德西韦（Remdesivir）治疗2019-nCoV新型冠状病毒临床研究，为抗击疫情带来曙光。 2月2日上午，国家药监局药品评审中心（CDE）网站显示，新型冠状病毒感染肺炎的潜在有效药物瑞德西韦（remdesivir）临床试验申请已经获受理。受理文件显示，注册企